Literature DB >> 33842242

Ratio of CA19-9 level to total bilirubin as a novel prognostic indicator in patients with pancreatic head carcinoma following curative resection.

Wen-Li Xu1, Jing Wang1, Shao-Cheng Lyu1, Lin Zhou1, Qiang He1, Ren Lang1.   

Abstract

BACKGROUND: Ratio of carbohydrate antigen 19-9 level to total bilirubin (CA19-9/TB) is used to reduce the influence of obstructive jaundice on the concentration of CA19-9, thereby determining the correlation between CA19-9/TB and tumor recurrence or long-term prognosis of patients with pancreatic head cancer (PHC).
METHODS: In this study, a total of 339 patients were enrolled. The optimal cut-off value of CA19-9/TB was determined by ROC curve based on preoperative CA19-9/TB and 1-year survival, and the patients were divided into low-ratio group (Group 1) and high-ratio group (Group 2) accordingly. Univariate and multivariate analyses were performed to screen out the risk factors affecting postoperative recurrence and long-term prognosis of PHC.
RESULTS: The best cut-off value of CA19-9/TB was 7.7. [area under curve (AUC), 0.599, 95% CI: 0.533-0.666] Compared with Group 1, Group 2 had lower CA19-9, higher TB and lymph node metastasis rate (P<0.05). The 1-, 2- and 3-year disease-free survival (DFS) rates of patients in Group 1 and Group 2 were 70.1%, 44.3% and 30.8%, 39.9%, 17.1% and 13.6%, respectively (P=0.000), and the 1-, 2- and 3-year overall survival (OS) rates were 81.5%, 52.1% and 31.5%, 53.7%, 20.5% and 14.2%, respectively (P=0.000). Multivariate analysis showed that CA19-9/TB, portal vein invasion and lymph node metastasis were independent risk factors for postoperative tumor recurrence and long-term survival of PHC.
CONCLUSIONS: Compared with CA19-9 alone, CA19-9/TB is more valuable in judging postoperative tumor recurrence and long-term survival of PHC. The lower the ratio, the better the long-term prognosis. 2021 Gland Surgery. All rights reserved.

Entities:  

Keywords:  Pancreatic head carcinoma (PHC); carbohydrate antigen 19-9 (CA19-9); pancreaticoduodenectomy; prognosis; total bilirubin

Year:  2021        PMID: 33842242      PMCID: PMC8033065          DOI: 10.21037/gs-20-720

Source DB:  PubMed          Journal:  Gland Surg        ISSN: 2227-684X


  24 in total

1.  Cancer statistics, 2018.

Authors:  Rebecca L Siegel; Kimberly D Miller; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2018-01-04       Impact factor: 508.702

2.  The use of adjusted preoperative CA 19-9 to predict the recurrence of resectable pancreatic cancer.

Authors:  Chang Moo Kang; Jun Young Kim; Gi Hong Choi; Kyung Sik Kim; Jin Sub Choi; Woo Jung Lee; Byong Ro Kim
Journal:  J Surg Res       Date:  2007-04-09       Impact factor: 2.192

3.  Pancreatectomy with Mesenteric and Portal Vein Resection for Borderline Resectable Pancreatic Cancer: Multicenter Study of 406 Patients.

Authors:  Giovanni Ramacciato; Giuseppe Nigri; Niccolò Petrucciani; Antonio Daniele Pinna; Matteo Ravaioli; Elio Jovine; Francesco Minni; Gian Luca Grazi; Piero Chirletti; Giuseppe Tisone; Niccolò Napoli; Ugo Boggi
Journal:  Ann Surg Oncol       Date:  2016-02-18       Impact factor: 5.344

4.  Prognostic Impact of Portal System Invasion in Pancreatic Cancer Based on Image Classification.

Authors:  Daishi Morimoto; Suguru Yamada; Kenta Murotani; Fuminori Sonohara; Hideki Takami; Masaya Suenaga; Masamichi Hayashi; Yukiko Niwa; Mitsuru Tashiro; Norifumi Hattori; Naoki Iwata; Mitsuro Kanda; Chie Tanaka; Daisuke Kobayashi; Goro Nakayama; Masahiko Koike; Michitaka Fujiwara; Tsutomu Fujii; Yasuhiro Kodera
Journal:  Pancreas       Date:  2018 Nov/Dec       Impact factor: 3.327

5.  CA19-9 serum levels in obstructive jaundice: clinical value in benign and malignant conditions.

Authors:  Daniele Marrelli; Stefano Caruso; Corrado Pedrazzani; Alessandro Neri; Eduardo Fernandes; Mario Marini; Enrico Pinto; Franco Roviello
Journal:  Am J Surg       Date:  2009-04-17       Impact factor: 2.565

6.  Elevation of carbohydrate antigen 19.9 in benign hepatobiliary conditions and its correlation with serum bilirubin concentration.

Authors:  S L Ong; A Sachdeva; G Garcea; G Gravante; M S Metcalfe; D M Lloyd; D P Berry; A R Dennison
Journal:  Dig Dis Sci       Date:  2008-05-09       Impact factor: 3.199

Review 7.  Prognostic and predictive markers in pancreatic adenocarcinoma.

Authors:  Nha Le; Malin Sund; Alessio Vinci
Journal:  Dig Liver Dis       Date:  2015-11-14       Impact factor: 4.088

8.  Prognostic role of the length of tumour-vein contact at the portal-superior mesenteric vein in patients having surgery for pancreatic cancer.

Authors:  T Imamura; Y Yamamoto; T Sugiura; Y Okamura; T Ito; R Ashida; K Ohgi; A Todaka; A Fukutomi; T Aramaki; K Uesaka
Journal:  Br J Surg       Date:  2019-10-18       Impact factor: 6.939

9.  Pancreatic cancer: challenges and opportunities.

Authors:  Huiyun Zhu; Tuo Li; Yiqi Du; Min Li
Journal:  BMC Med       Date:  2018-11-22       Impact factor: 8.775

10.  Usefulness of Carbohydrate Antigen 19-9 Test in Healthy People and Necessity of Medical Follow-up in Individuals with Elevated Carbohydrate Antigen 19-9 Level.

Authors:  Sang Pyo Lee; In-Kyung Sung; Jeong Hwan Kim; Sun-Young Lee; Hyung Seok Park; Chan Sup Shim
Journal:  Korean J Fam Med       Date:  2019-04-08
View more
  3 in total

1.  Preoperative Alkaline Phosphatase-adjusted CA19-9 as a Superior Prognosticator for Extrahepatic Biliary Tract Cancer With Jaundice.

Authors:  Shinichi Ikuta; Tsukasa Aihara; Takayoshi Nakajima; Meidai Kasai; Naoki Yamanaka
Journal:  Cancer Diagn Progn       Date:  2022-09-03

2.  Adjusting CA19-9 values with clinical stage and bilirubin to better predict survival of resectable pancreatic cancer patients: 5-year-follow-up of a single center.

Authors:  Zuowei Wu; Pengcheng Zhao; Zihe Wang; Xing Huang; Chao Wu; Mao Li; Li Wang; Bole Tian
Journal:  Front Oncol       Date:  2022-07-29       Impact factor: 5.738

3.  Quantitative definitions of prognostic indicators of resectable pancreatic cancer.

Authors:  Hang Sun; Huayu Yang; Yilei Mao
Journal:  Gland Surg       Date:  2022-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.